Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker

Hypertension

Volumn 50, Issue 1, 2007, Pages 89-95

  Skov, Karin ^a,b   Eiskjær, Hans ^b   Hansen, Hans Erik ^b   Madsen, Jens Kristian ^c   Kvist, Stinne ^b   Mulvany, Michael John ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c VIBORG HOSPITAL   (Denmark)

Author keywords

Angiotensin II receptor blocker; Familial hypertension; Left ventricular mass; Prophylactic treatment; Randomized clinical trial; Renal vascular resistance

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HEREDITARY HYPERTENSION; HIGH RISK POPULATION; HUMAN; INTERVENTION STUDY; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGENY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYNCOPE; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT WITHDRAWAL;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEART VENTRICLES; HUMANS; HYPERTENSION; MALE; RENAL CIRCULATION; TETRAZOLES; VASCULAR RESISTANCE;

EID: 34250829757     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.089532     Document Type: Article

References (41)

1. Kaplan NM, Opie LH. Controversies in hypertension. Lancet. 2006;367:168-176.
2. Cui J, Hopper JL, Harrap SB. Genes and family environment explain correlations between blood pressure and body mass index. Hypertension. 2002;40:7-12.
3. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-1697.
4. Chobanian AV. Prehypertension revisited. Hypertension. 2006;48:812-814.
5. Schunkert H. Pharmacotherapy for prehypertension-mission accomplished? N Engl J Med. 2006;354:1742-1744.
6. Conen D, Martina B. Treating prehypertension. N Engl J Med. 2006;355:417-418.
7. Skov K, Julius S, Nesbitt S, Mulvany MJ. Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies. Curr Opin Cardiol. 2002;17:380-384.
8. Giudicelli JF, Freslon JL, Glasson S, Richer C. Captopril and hypertension development in the SHR. Clin Exp Hypertens. 1980;2:1083-1096.
9. Skov K, Mulvany MJ. Structure of renal afferent arterioles in the pathogenesis of hypertension. Acta Physiol Scand. 2004;181:397-405.
10. Naelten G, Liu KL, Chapuis B, Lo M. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats. Am J Hypertens. 2005;18:699-706.
11. Skov K, Madsen JK, Hansen HE, Zagato L, Frandsen E, Bianchi G, Mulvany MJ. Renal haemodynamics are not related to genotypes in offspring of parents with essential hypertension. Journal of the Renin-Angiotensin-Aldosterone System. 2006;7:47-55.
12. van Hooft I, Grobbee DE, Derkx FH, de Leeuw PW, Schalekamp MA, Hofman A. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med. 1991;324:1305-1311.
13. van Hooft I, Grobbee DE, Waal-Manning HJ, Hofman A. Hemodynamic characteristics of the early phase of primary hypertension. The Dutch Hypertension and Offspring Study. Circulation. 1993;87:1100-1106.
14. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
15. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. Brit Med J. 2001;322:531-536.
16. Hansen KW, Poulsen PL, Ebbehoj E, Mogensen CE. What is hypertension in diabetes? Ambulatory blood pressure in 137 normotensive and normoalbuminuric Type 1 diabetic patients. Diabet Med. 2001;18:370-373.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613-618.
19. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781-788.
20. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, Takano K. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40:28-33.
21. Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos DV. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem. 2004;4:483-486.
22. Harrap SB, Nicolaci JA, Doyle AE. Persistent effects on blood pressure and renal haemodynamics following chronic angiotensin converting enzyme inhibition with perindopril. Clin Exp Pharmacol Physiol. 1986;13:753-765.
23. Gillies LK, Lu M, Wang H, Lee RM. AT1 receptor antagonist treatment caused persistent arterial functional changes in young spontaneously hypertensive rats. Hypertension. 1997;30:1471-1478.
24. Skov K, Fenger-Gron J, Mulvany MJ. Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Hypertension. 1996;28:464-471.
25. Wu JN, Berecek KH. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension. 1993;22:139-146.
26. Smallegange C, Kline RL, Adams MA. Transplantation of enalapril-treated kidneys confers persistent lowering of arterial pressure in SHR. Hypertension. 2003;42:932-936.
27. Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hypertens. 2000;13:1045-1048.
28. Willemsen JM, Rabelink TJ, Boer P, Gaillard CA. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. J Hum Hypertens. 2004;18:857-863.
29. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs. 2002;62:1253-1287.
30. Mulvany MJ, Persson AE, Andresen J. No persistent effect of angiotensin converting enzyme inhibitor treatment in Milan hypertensive rats despite regression of vascular structure. J Hypertens. 1991;9:589-593.
31. Mancia G, Ulian L, Parati G, Trazzi S. Increase in blood pressure reproducibility by repeated semi-automatic blood pressure measurements in the clinic environment. J Hypertens. 1994;12:469-473.
32. Trazzi S, Mutti E, Frattola A, Imholz B, Parati G, Mancia G. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens. 1991;9:115-119.
33. Asmar R, Lacourciere Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens. 2000;18:1683-1690.
34. Staessen JA, Thijs L, O'Brien ET, Bulpitt CJ, de Leeuw PW, Fagard RH, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, Safar ME. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens. 2002;15:835-843.
35. Jennings G, Korner PI, Sudhir K, Esler M, Angus JA, Laufer E. Evidence for a role for the cardiovascular amplifiers in human primary hypertension. Clin Exp Pharmacol Physiol. 1991;18:37-41.
36. Trimarco B, Rosiello G, Sarno D, Lorino G, Rubattu S, DeLuca N, Volpe M. Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. Am J Cardiol. 1994;74:36A-42A.
37. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG TS. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139-185.
38. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
39. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
40. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682-1686.
41. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548-1557.